Janssen Pharmaceutica NV has identified interleukin-17A (IL-17A)/IL-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of psoriasis, rheumatoid arthritis, radiographic axial spondyloarthritis (ankylosing spondylitis), multiple sclerosis, asthma, chronic obstructive pulmonary disease, atopic dermatitis and systemic lupus erythematosus, among others.
McMaster University has synthesized radiolabeled-drug conjugates comprising a glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA)-targeting moiety covalently linked to a DNA intercalating agent through a radiolabeling moiety reported to be useful for diagnosis and treatment of cancer.
Carbonic anhydrase IX (CAIX) is overexpressed in the hypoxic tumor environment and is thought to help drive tumor progression and metastasis by generating protons that acidify the area. Therefore, inhibiting the enzyme may be effective as an anticancer treatment.
Moonlight Therapeutics Inc.’s IND application for MOON-101 has been cleared by the FDA, paving the way for a first clinical trial in adults and children with peanut allergy.
Inhibiting human monoamine oxidase (MAO)-B to increase the availability of monoamine neurotransmitters is a clinically approved strategy for treating Parkinson’s disease, yet available inhibitors lack efficacy or increase risk of adverse events. Researchers at Hefei University of Technology and collaborators started from the clinically improved MAO-B inhibitor safinamide and generated various derivatives, among which [I] and [II] emerged as the most promising.
Researchers from Cincinnati Children’s Hospital Medical Center and collaborating institutions in the U.S. have developed a novel approach using allergen-encoding mRNA encapsulated in lipid nanoparticles (LNPs) for both therapy and prevention of allergic responses.
RSS
